Most biotechs are set to rally into 2023 following suppression and release of XBI through institutional channels. Components inside of XBI that initially contributed to its rise and gains over the years will be the source to start the process again.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.